S. Korn (Mainz, Germany), M. Lommatzsch (Rostock, Germany)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
The role of cathepsin S in the development of inflammation in patients with severe bronchial asthma
A. Kraposhina (Krasnoyarsk (Krasnoyarsk), Russian Federation), I. Demko (Krasnoyarsk (Krasnoyarsk), Russian Federation), E. Sobko (Krasnoyarsk (Krasnoyarsk), Russian Federation), N. Gordeeva (Krasnoyarsk (Krasnoyarsk), Russian Federation), I. Soloveva (Krasnoyarsk (Krasnoyarsk), Russian Federation), M. Mamaeva (Krasnoyarsk (Krasnoyarsk), Russian Federation)
|   |
Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada
S. Szabo (Vancouver, Canada), A. Gendron (Montréal, Canada), A. Deighton (Vancouver, Canada), R. Dragan (Winnipeg, Canada), G. Detillieux (Winnipeg, Canada), H. Prior (Winnipeg, Canada), S. Noorduyn (Mississauga, Canada)
| |
Asthma diagnosis and severity assessment, can microRNAs help? A pilot study
A. Kyyaly (Southampton, United Kingdom), T. Sanchez-Elsner (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom), S. Arshad (Southampton, United Kingdom)
| |
Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry
S. Graff (Liege, Belgium), G. Brusselle (Ghent, Belgium), S. Hanon (Brussels, Belgium), C. Sohy (Louvain, Belgium), L. Dupont (Leuven, Belgium), R. Peche (Charleroi, Belgium), A. Michils (Brussels, Belgium), C. Pilette (Brussels, Belgium), G. Joos (Ghent, Belgium), R. Louis (Liege, Belgium), F. Schleich (Liege, Belgium)
| |
Intermediate-onset asthma: similarities and differences with early and late-onset
M. Turrin (PADOVA, Italy), M. Rizzo (PADOVA, Italy), S. Tonin (PADOVA, Italy), K. Lokar Oliani (PADOVA, Italy), M. Bonato (PADOVA, Italy), M. Cosio (Montreal, Canada), M. Saetta (PADOVA, Italy), S. Baraldo (PADOVA, Italy)
| |
Raised FeNO in optimally-treated severe asthma identifies persistent eosinophilic chemotactic pull towards the airway
S. Couillard (Oxford, United Kingdom), R. Shrimanker (Oxford, United Kingdom), G. Hynes (Oxford, United Kingdom), C. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), A. Hayman (Oxford, United Kingdom), S. Thulborn (Oxford, United Kingdom), A. Moran (Oxford, United Kingdom), S. Poole (Oxford, United Kingdom), T. Powell (Oxford, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom), A. Mansur (Birmingham, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), L. Heaney (Oxford, United Kingdom), S. Fowler (Manchester, United Kingdom), P. Bradding (Leicester, United Kingdom), I. Pavord (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom)
| |
Markers of pulmonary injury and inflammation are elevated in the serum of patients with chronic cough
J. Smith (Manchester (Greater Manchester), United Kingdom), D. Lamb (Biberach an der riß, Germany), R. Dockry (Manchester (Greater Manchester), United Kingdom), A. Schoenleber (Biberach an der riß, Germany), E. Benediktus (Biberach an der riß, Germany)
| |
Transcriptomic profiles of eosinophilic asthmatic patients classified according to their atopic status
S. Gerday (Liege, Belgium), F. Schleich (Liege, Belgium), F. Guissard (Liege, Belgium), M. Henket (Liege, Belgium), V. Paulus (Liege, Belgium), R. Louis (Liege, Belgium)
| |
Aero-allergen sensitization in a general population: data from the LEAD population cohort study
F. Kölli (Wien, Austria), M. Breyer (Wien, Austria), S. Hartl (Wien, Austria), G. Kohlböck (Wien, Austria), O. Burghuber (Wien, Austria), W. Pohl (Wien, Austria), T. Sigsgaard (Aarhus, Denmark), E. Wouters (Maastrich, Denmark), R. Breyer-Kohansal (Wien, Austria)
| |
Immunoglobulin G and subclasses in COPD exacerbator phenotype: levels in exacerbation time and clinical stability
J. Juanola Pla (Mataró, Spain), R. Boixeda Viu (Mataró, Spain), I. Moreno Hernandez (Vilassar de Dalt, Spain), M. De La Torre Terron (Mataró, Spain), M. Bartolomé Regué (Mataró, Spain), A. Serrano Fores (Mataró, Spain), A. Montero Rodriguez (Mataró, Spain), E. Palomera Fanegas (Mataró, Spain), M. Serra Prat (Mataró, Spain), J. Almirall Pujol (Mataró, Spain)
| |
Impact of blood eosinophil variability in asthma: a real-life population study.
N. Toledo Pons (Palma, Spain), J. Van Boven (Groningen, Netherlands), J. Muncunill (Palma, Spain), A. Millán Pons (Palma, Spain), M. Román-Rodríguez (Palma, Spain), B. López-Andrade (Palma, Spain), C. Almonacid (Madrid, Spain), D. Velasco Álvarez (Madrid, Spain), J. Kocks (Groningen, Netherlands), B. Cosío (Palma, Spain)
| |
Inflammatory phenotypes of severe exacerbation of COPD, a clinico-laboratory characterization.
K. Ramaraju (Coimbatore (Tamil Nadu), India), R. Sankaran (Coimbatore (Tamil Nadu), India), A. Kaza (Coimbatore (Tamil Nadu), India), T. Sairam (Coimbatore (Tamil Nadu), India)
| |
Higher expression of lipoxygenase and cyclooxygenase pathways in bronchial than alveolar lavage from allergic asthmatics
N. van der Burg (Lund, Sweden), H. Stenberg (Lund, Sweden), Z. Diamant (Lund, Sweden), L. Bjermer (Lund, Sweden), E. Tufvesson (Lund, Sweden)
| |
Adult women with asthma and diabetes have increased body weight and fat percentage compared to women with only diabetes.
A. Bossios (Stockholm, Sweden), D. Andersson (Stockholm, Sweden), D. Eriksson-Hogling (Stockholm, Sweden), M. Rydén (Stockholm, Sweden)
| |
Sensitization to aeroallergens is dominant in overweight to obese asthmatic males but not in females.
B. Nwaru (Gothenburg, Sweden), H. Kankaanranta (Gothenburg, Sweden), M. Rådinger (Gothenburg, Sweden), J. Lötvall (Gothenburg, Sweden), B. Lundbäck (Gothenburg, Sweden), L. Ekerljung (Gothenburg, Sweden), A. Bossios (Stockholm, Sweden)
| |
Plasma adiponectin and risk of asthma: observational and Mendelian randomization studies in up to 557,801 individuals
M. Nielsen (Herlev, Denmark), B. Nordestgaard (Herlev, Denmark), M. Benn (Copenhagen, Denmark), Y. Çolak (Herlev, Denmark)
| |
Clinical variables and protein biomarkers associated with blood eosinophil count and asthma in young adults
M. Kere (Stockholm, Sweden), S. Björkander (Stockholm, Sweden), S. Klevebro (Stockholm, Sweden), M. Ödling (Stockholm, Sweden), S. Ekström (Stockholm, Sweden), I. Mogensen (Stockholm, Sweden), M. Van Hage (Stockholm, Sweden), A. Bergström (Stockholm, Sweden), I. Kull (Stockholm, Sweden), E. Melén (Stockholm, Sweden)
| |
Eosinophil-derived neurotoxin levels in serum are associated with asthma-like symptoms
R. Movérare (Uppsala, Sweden), M. Molin (Uppsala, Sweden), A. Malinovschi (Uppsala, Sweden), E. Pertsinidou (Uppsala, Sweden), A. Sjölander (Uppsala, Sweden), C. Janson (Uppsala, Sweden)
| |
Sex Differences in Severe Asthma
A. Azim (Southampton, United Kingdom), C. Barber (Southampton, United Kingdom), L. Lau (Southampton, United Kingdom), M. Harvey (Southampton, United Kingdom), P. Dennison (Southampton, United Kingdom), T. Brown (Portsmouth, United Kingdom), T. Jones (Portsmouth, United Kingdom), S. Elliot (Portsmouth, United Kingdom), A. Chauhan (Portsmouth, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom), P. Howarth (Southampton, United Kingdom)
| |
Sputum Interleukin 5 in eosinophilic and non-eosinophilic severe asthma
A. Azim (Southampton(Dorset), United Kingdom), C. Barber (Southampton(Dorset), United Kingdom), K. Gove (Southampton(Dorset), United Kingdom), T. Brown (Southampton(Dorset), United Kingdom), T. Jones (Southampton(Dorset), United Kingdom), S. Elliot (Southampton(Dorset), United Kingdom), A. Chauhan (Southampton(Dorset), United Kingdom), P. Howarth (Southampton(Dorset), United Kingdom)
| |